

CLAIMS

1) Peptide having the following primary structure:

Asp-Pro-His-Lle-Lys-Leu-Gln-Leu-Gln-Ala-Glu

2) Peptide having sequence-identity of at least 60% with the following sequence:

5 Asp-Pro-His-Lle-Lys-Leu-Gln-Leu-Gln-Ala-Glu

3) Peptide having electric-charge homology or hydrophilia or hydrophobicity or solvent-exposure rate or three-dimensional conformation of at least 60% with the following sequence:

10 Asp-Pro-His-Lle-Lys-Leu-Gln-Leu-Gln-Ala-Glu

4) Peptidic or non-peptidic molecules showing conformational similarity or functional-group disposition similarity, of at least 60% with the following sequence:

15 Asp-Pro-His-Lle-Lys-Leu-Gln-Leu-Gln-Ala-Glu

5) The use of the peptides of claims 1 or 2 or 3 or 4 as inhibitors of platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF).

6) The use of the peptides of claims 1 or 2 or 3 or 4
20 for the preparation of a pharmacological compound able to affect cell proliferation.

7) The use of the peptides of claims 1 or 2 or 3 or 4 for the preparation of a pharmacological compound able to affect cell migration and tumor cell migration
25 toward potential metastatis sites.

8) The use of the peptides of claims 1 or 2 or 3 or 4 as inhibitors of primary tumor growth and metastasis.

9) The use of the peptides of claims 1 or 2 or 3 or 4 for the preparation of a pharmacological compound to be

used as adjuvant for the treatment of neoplastic and vascular diseases.

10) The use of the peptides of claims 1 or 2 or 3 or 4 for the preparation of a pharmacological compound to be
5 used for the treatment of vascular diseases.

11) The use of the peptides of claims 1 or 2 or 3 or 4 for the preparation of a pharmacological compound to be used for the treatment of trombotic events and related phatologies.